Zuclopenthixol

Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Unlabeled Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Substrate of
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names

Europe

Austria: Cisordinol; Belgium: Clopixol; Bulgaria: Clopixol; Denmark: Cisordinol; Estonia: Cisordinol; Finland: Cisordinol; France: Clopixol; Germany: Ciatyl, Clopixol; Greece: Clopixol; Hungary: Cisordinol; Ireland: Clopixol; Italy: Clopixol; Luxembourg: Clopixol; Netherlands: Cisordinol, Clopixol; Poland: Clopixol; Portugal: Cisordinol; Romania: Clopixol; Slovakia: Cisordinol; Slovenia: Clopixol; Spain: Cisordinol, Clopixol; Sweden: Cisordinol, Clopixol; UK: Clopixol.

North America

Canada: Clopixol.

Latin America

Argentina: Clopixol, Zuclopentixol; Brazil: Clopixol; Mexico: Clopixol.

Drug combinations

Chemistry

Zuclopenthixol: C~22~H~25~ClN~2~OS. Mw: 400.96. (Z)-4-[3-(2-Chlorothioxanthen-9-ylidene)propyl]-1-piperazineethanol. CAS-53772-83-1.

Pharmacologic Category

Antipsychotics; Thioxanthenes. Typical Antipsychotic Agent. (ATC-code: N05AF05).

Mechanism of action

A thioxanthene antipsychotic with a piperazine side chain. Related to fluphenazine, cis(z)-clopenthixol is the active isomer of this neuroleptic. Blocks postsynaptic dopaminergic brain receptors.

Therapeutic use

Management of schizophrenia.

Pregnancy and lactiation implications

Use caution during pregnancy. Not recommended in nursing women.

Unlabeled use

Bipolar disorder, psychoses. Agitated states.

Contraindications

Hypersensitivity to zuclopenthixol, thioxanthenes, or any component of the formulation. Acute intoxication (ethanol, barbiturate, or opioid). Severe CNS depression. Coma. Subcortical brain damage. Circulatory collapse. Blood dyscrasias. Pheochromocytoma.

Warnings and precautions

May alter cardiac conduction (life-threatening arrhythmias occurred). Avoid use in underlying QT prolongation, in patients taking medicines which prolong QT interval, or cause polymorphic ventricular tachycardia. May cause anticholinergic effects (blurred vision, constipation, urinary retention, xerostomia)(use with caution in decreased gastrointestinal motility, paralytic ileus, urinary retention, BPH, xerostomia, or visual problems). Myelosuppression (e.g. leukopenia, agranulocytosis) observed with antipsychotic use (use contraindicated in bone marrow suppression). Antipsychotic use associated with esophageal dysmotility and aspiration (use with caution in risk of pneumonia (e.g. Alzheimer’s disease). May cause extrapyramidal symptoms, including pseudoparkinsonism, acute dystonic reactions, akathisia, and tardive dyskinesia (risk of these reactions high relative to other neuroleptics). Use may be associated with neuroleptic malignant syndrome (risk may be increased in Parkinson’s disease or Lewy body dementia). May cause orthostatic hypotension (use with caution in cerebrovascular disease, cardiovascular disease, hypovolemia, or concurrent medication use which may predispose to hypotension/bradycardia). May be associated with pigmentary retinopathy. May be sedating (use with caution). Impaired core body temperature regulation may occur. Use with caution in severe cardiovascular disease. Zuclopenthixol not approved for use in elderly patients with dementia-related psychosis. Use with caution in narrow-angle glaucoma (may be exacerbated by cholinergic blockade), in hepatic impairment, in myasthenia gravis (may be exacerbated by cholinergic blockade), and in Parkinson’s disease (may be more sensitive to adverse effects). Use with caution in breast cancer or other prolactin-dependent tumors (elevates prolactin levels), in renal impairment, in respiratory disease, and in risk of seizures, including patients with history of seizures, head trauma, brain damage (subcortical-contraindicated), alcoholism, or concurrent therapy with medications which may lower seizure threshold. May mask toxicity of other drugs or conditions (e.g. intestinal obstruction, Reye’s syndrome, brain tumor) due to antiemetic effects.

Information

Legal

Legal Notice
Privacy Policy
Cookie Policy

Contact

Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart